Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Hepatocellular 7Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Hemangiosarcoma 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 2spartalizumab 1siltuximab 1sabatolimab 1ruxolitinib 1pelcitoclax 1fludarabine phosphate 1ethanolamine oleate 1durvalumab 1Whole-Body Irradiation 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tacrolimus 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Pentostatin 1Pentetic Acid 1Ondansetron 1NIS-793 1Mycophenolic Acid 1Methotrexate 1In Situ Hybridization, Fluorescence 1Immunoglobulin G 1Immunoenzyme Techniques 1Flow Cytometry 1Filgrastim 1Ethanol 1Edetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Polycythemia Vera × spartalizumab × Clear all
NCT04283526 2021-03-04

Study of Select Combinations in Adults With Myelofibrosis

Novartis

Phase 1 Withdrawn
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡